HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.
Stocks · News reference
Monte Rosa Therapeutics Announces $50M Milestone Payment From Novartis On First Patient Visit In Phase 2 Study Of MRT-6160 In Sjögren's Disease
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.
8-K filing — Monte Rosa Therapeutics, Inc. (GLUE)
Filed: 2026-10-01 AccNo: 0001193125-26-409833 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway